Article on Nuvec®’s Potential in RNA Therapeutics

Thalia Therapeutics

30/07/2025 13:55

RNS Number : 2400T

N4 Pharma PLC

30 July 2025

 

 

 

30 July 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

New Article on Nuvec®'s Potential in RNA Therapeutics

 

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to share a new article published on its website: "Reimagining RNA therapeutics: why delivery is the defining challenge-and how Nuvec® is poised to solve it."

 

The article is on N4 Pharma's interactive investor hub here: https://n4pharma.com/s/25d785

 

-      Ends -

 

For more information please contact:

 

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
Via N4 Pharma Investor Hub:investors.n4pharma.com
https://n4pharma.com/link/yMNQve
SP Angel CorporateFinance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44 (0)20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with commercial partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAPKKBPBBKDDON